Premier Medical Corporation

Name

Premier Medical Corporation

Legal name

Premier Medical Corporation Private Limited

Website

https://premiermedcorp.com

Company type

Private

Founded year

1996

Operating status

Operating

Headcount range

501–1,000 employees

Ownership category

akta.pro rank

Product category

In Vitro Diagnostics (Rapid Diagnostic Tests)

NAICS

In-Vitro Diagnostic Substance Manufacturing (325413), Medical, Dental, and Hospital Equipment and Supplies Merchant Wholesalers (423450), Medical Equipment and Supplies Manufacturing (33911)

SIC

In Vitro & In Vivo Diagnostic Substances (2835), Wholesale-Medical, Dental & Hospital Equipment & Supplies (5047)

akta.pro primary industry

Remote Diagnostics & Home Testing Devices (Connected POC/At-Home Diagnostic Readers) (HLAHACAL)

akta.pro secondary industries

Vaccines & Public Health Product Distribution (CRAOAHAI), Personal Medical Devices & Home Diagnostics (Thermometers, Blood Pressure Monitors, Glucose Meters, Rapid Tests) (CRADAMAK), Medical Supplies & Consumables Wholesale (Non-Device) (CRAOAHAE)

Keywords

• Rapid diagnostic tests
• Lateral flow assays
• Point-of-care diagnostics
• Infectious disease testing
• In vitro diagnostics

Headquarters

HQ city

Ahmedabad

HQ country

India

HQ region

Asia

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Supply Chain, Operations, Personnel, Technology or R&D, Marketing or Sales, Infrastructure

Revenue model

1. Point-of-Care Rapid Diagnostic Tests: Premier Medical generates revenue through the sale of rapid diagnostic tests for infectious diseases including Malaria, HIV, Hepatitis, Syphilis, Dengue, and Sickle Cell. Tests are sold as kits with various pack sizes (5T, 10T, 25T, 30T, 50T, 60T, 100T per kit). Products are sold to healthcare professionals, laboratories, hospitals, government health centers, distributors, and retailers globally.

Pricing tiers

Go-to-market motion1 record

Distribution channels4 records

Marketing channels3 records

Core offering

Premier Medical Corporation manufactures and globally distributes cost-effective point-of-care rapid diagnostic tests (RDTs) using lateral flow (immunochromatographic) assay technology. The product portfolio covers infectious diseases including Malaria, HIV, Hepatitis B/C, Syphilis, Dengue, and COVID-19, plus hemoglobinopathy screening (Sickle Cell), in single-analyte and combo card formats for professional and self-test use. Kits are sold in bulk to healthcare professionals, laboratories, hospitals, government health ministries, distributors, retailers, and international public health procurement organizations across 100+ countries.

Product overview

Premier Medical Corporation offers a portfolio of lateral flow rapid diagnostic tests under the First Response® and Sure Status® brands for point-of-care in vitro diagnostics. The product line includes rapid tests for infectious diseases (Malaria, HIV, Syphilis, HCV, Hepatitis B, Dengue, COVID-19), genetic disorders (Sickle Cell), and combination tests (HIV/Syphilis, HIV/HCV). Products are available in professional use versions and self-test formats, featuring various antigen/antibody detection methods including HRP2, pLDH, and immunochromatographic assays. Most tests provide qualitative results within 5-30 minutes using whole blood, serum, or plasma specimens. The company operates under ISO 13485:2016 with WHO Prequalification and CE marking for multiple products.

Differentiator

Problem solved

Functional benefit

Brands

• First Response®: Primary brand for rapid diagnostic tests including Malaria, HIV, Hepatitis, and Syphilis tests.
• Sure Status®

Products and services

• First Response® Malaria Antigen P.falciparum (HRP2) Card Test Rapid qualitative in vitro diagnostic test for detection of P. falciparum specific HRP2 antigen, performed by trained users in laboratory or point-of-care settings. WHO-prequalified.
• First Response® Malaria Ag pLDH/HRP2 Combo Card Test Rapid qualitative screening test for detection of P. falciparum, P. vivax, P. ovale and P. malariae with a detection threshold of 200 parasites per microliter of blood. WHO-prequalified and ICMR-validated.
• First Response® Malaria Ag. P.f./P.v. Card Test Rapid qualitative screening test for the detection of P. falciparum and P. vivax using dual-antigen detection (HRP2 and pLDH). WHO-prequalified with reported 100% specificity.
• First Response® Malaria Ag. P.falciparum (HRP2/pLDH) Combo Card Test Next-generation rapid diagnostic for P. falciparum infections detecting HRP2 and pLDH antigens with 100% sensitivity and 100% specificity, results in 20–30 minutes, whole blood specimen, ROW regulatory version.
• First Response® Malaria Ag. P. falciparum (HRP2/pLDH) Card Test Rapid test for detection of Malaria Ag P. falciparum specific to HRP2 and/or pLDH in human whole blood using a single-line dual-antigen detection system, with 100% sensitivity and specificity, results in 20–30 minutes.
• First Response® Malaria Ag. P.f. (HRP2)/P.f. (pLDH)/P.v. (pLDH) Test Rapid qualitative screening test for detection of histidine rich protein 2 (HRP2) antigen and plasmodium lactate dehydrogenase (pLDH) antigen that differentiates P. falciparum and P. vivax infections in whole blood specimens, results in 20–30 minutes.
• First Response® HIV 1-2.O Card Test (Version 2.0) Rapid qualitative screening test for detection of antibodies specific to HIV-1 (including Group O) and HIV-2 in human serum, plasma, or venous and capillary whole blood. WHO-prequalified, validated by NICD and in Ghana and Zimbabwe.
• First Response® HIV 1+2/Syphilis Combo Card Test Rapid qualitative screening test for the detection of antibodies (IgG & IgM) specific to HIV (type 1 & 2) and Treponema pallidum in human serum, plasma, or venous and capillary whole blood. WHO-prequalified.
• First Response® HIV 1+2 / HCV Combo Card Test Immunochromatographic assay for qualitative detection of antibodies specific for HIV-1&2 and/or Hepatitis C in human whole blood, serum, or plasma with 100% sensitivity and specificity, results in 20–25 minutes. CDSCO-approved.
• First Response® Syphilis Anti-TP Card Test Rapid qualitative screening test for the detection of antibodies of all classes specific to Treponema pallidum in human serum, plasma, or whole blood. WHO-prequalified, CE-certified, and NIB-validated.
• First Response® HCV Card Test Chromatographic immunoassay for the qualitative detection of antibodies against hepatitis C virus (HCV Ab) in human serum, plasma, or whole blood (venous & capillary blood) specimens. WHO-prequalified.
• First Response® HBsAg Card Test Chromatographic immunoassay for qualitative detection of Hepatitis B surface antigen in serum, plasma, or whole blood specimens. CE-marked.
• First Response® Dengue (NS1) Card Test Lateral flow chromatographic immunoassay for qualitative detection of dengue NS1 antigen (DEN1, 2, 3, 4) in human serum, plasma, or whole blood. Evaluated by NABL-accredited laboratory.
• First Response® HIV 1-2.O Card Test (Self Test) In vitro diagnostic medical device for self-testing by untrained/lay users to detect antibodies specific to HIV-1 and HIV-2 in human whole blood.
• First Response® HCV Card Test (Self Test) In vitro diagnostic medical device for self-testing by untrained/lay users to detect antibodies specific to HCV in human whole blood. CDSCO-approved for export only.
• First Response® Sickle Cell Detection Card Test Rapid qualitative in vitro diagnostic for early screening of hemoglobin variants Type-A and Type-S with >99% sensitivity and specificity, results in 5–10 minutes, whole blood specimen, CDSCO-approved.
• Sure Status® COVID-19 Antigen Card Test Rapid antigen test for detection of SARS-CoV-2. WHO Emergency Use Listed (EUL 0590-010-00).

Quantifiable outcome

• 100% Sensitivity and 100% Specificity for multiple products including HIV, Syphilis, HCV, and Malaria Combo tests
• +4 more outcomes

Named customers10 records

Segments4 records

Ideal customer profiles4 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Two partnerships are on record, tiered core.

• VIA Global HealthcoreChannel Partner/ Reseller/ Distributor · 20 May 2023FIND and VIA Global Health partnership provides new routes to market for regional and global manufacturers of high-quality diagnostic tests. VIA Global Health marketplace delivers medical products to over 80 countries. Premier Medical tests made available for purchase from VIA Global Health by buyers for low- and middle-income markets.
• FINDcoreStrategic or Co-development Partner · 24 February 2022FIND (Foundation for Innovative New Diagnostics) partnered with Premier Medical to accelerate availability of affordable COVID-19 self-tests in low- and middle-income countries. Support package including US$7 million investment. CEO Nilesh Mehta emphasized commitment to breaking healthcare barriers in LMICs through self-testing solutions.

Scale indicators7 records

Recent moves6 records

Direct peers

• Access Bio: US-Korean rapid diagnostic test maker specializing in Malaria, HIV, HBV/HCV and other infectious disease lateral flow assays, with extensive WHO PQ portfolio and global LMIC supply contracts — a direct competitor to Premier Medical.
• SD Biosensor: Korean IVD manufacturer of lateral flow rapid diagnostic tests for Malaria, HIV, HCV, Dengue, and other infectious diseases, with WHO PQ products and strong LMIC distribution — directly competing with Premier Medical in the same product categories.

Regional players

• Tulip Diagnostics (PerkinElmer): India-headquartered diagnostics manufacturer offering a broad range of rapid tests and reagents for Malaria, HIV, HCV, and other infectious diseases — competes with Premier Medical in the Indian and emerging market channels.
• Meril Diagnostics: India-based IVD manufacturer producing rapid diagnostic tests for infectious diseases including Malaria, HIV, HCV, Dengue, and HBsAg — a regional Indian peer with overlapping lateral flow product lines.

Emerging players

• Trinity Biotech: Ireland-based diagnostics company offering rapid HIV and infectious disease tests including lateral flow and point-of-care formats, with global distribution including LMIC markets.
• Mologic / Global Access Diagnostics: UK-based rapid diagnostic test developer with focus on affordable, high-quality lateral flow tests for global health, including Malaria and infectious disease tests — comparable product portfolio and LMIC mission.

Broad incumbents

• Bio-Rad Laboratories: Global diagnostics company with rapid test and immunoassay offerings for infectious disease screening including HIV and Hepatitis — overlaps with Premier Medical in IVD space.
• Revvity (formerly PerkinElmer): Large global diagnostics and life sciences company with point-of-care and rapid test offerings, including infectious disease screening — broader portfolio competitor to Premier Medical in LMIC and donor-funded markets.
• Abbott (Rapid Diagnostics / Alere): Global diagnostics giant with a large rapid diagnostics portfolio including Malaria, HIV, and infectious disease RDTs (e.g., BinaxNOW, Determine) — competes with Premier Medical at the upper end of the LMIC and donor-funded market.

Others

• FIND (Foundation for Innovative New Diagnostics): Global health product development partnership and investor in Premier Medical (US$7M grant in 2022); functions as an enabler/funder in the LMIC diagnostics ecosystem rather than a direct competitor.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

Compliance11 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles3 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Premier Medical Corporation